194 related articles for article (PubMed ID: 33989683)
1. Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH.
Chan CK; Mein CE; Glassman AR; Beaulieu WT; Calhoun CT; Jaffe GJ; Jampol LM; MacCumber MW; Maguire MG; Maturi RK; Salehi-Had H; Rofagha S; Sun JK; Martin DF;
Ophthalmology; 2021 Nov; 128(11):1592-1603. PubMed ID: 33989683
[TBL] [Abstract][Full Text] [Related]
2. Pneumatic Vitreolysis for the Treatment of Vitreomacular Traction Syndrome.
Özdemir HB; Özdek Ş; Hasanreisoğlu M
Turk J Ophthalmol; 2019 Sep; 49(4):201-208. PubMed ID: 31486607
[TBL] [Abstract][Full Text] [Related]
3. Anatomical and functional outcomes of pneumatic vitreolysis for treatment of vitreomacular traction with and without macular holes.
Baumann C; Sabatino F; Zheng Y; Johannigmann-Malek N; Maier M; Kaye SB; Patton N
Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2209-2215. PubMed ID: 35122133
[TBL] [Abstract][Full Text] [Related]
4. PNEUMATIC VITREOLYSIS FOR RELIEF OF VITREOMACULAR TRACTION.
Chan CK; Crosson JN; Mein CE; Daher N
Retina; 2017 Oct; 37(10):1820-1831. PubMed ID: 28099316
[TBL] [Abstract][Full Text] [Related]
5. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
[TBL] [Abstract][Full Text] [Related]
6. PNEUMATIC VITREOLYSIS VERSUS PARS PLANA VITRECTOMY IN FOCAL SYMPTOMATIC VITREOMACULAR TRACTION SYNDROME: A Randomized Trial.
Kumar V; Sonkar R; Verma S; Azad SV; Chawla R; Venkatesh P; Vohra R; Kumar A
Retina; 2022 Jul; 42(7):1277-1283. PubMed ID: 35723920
[TBL] [Abstract][Full Text] [Related]
7. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
[TBL] [Abstract][Full Text] [Related]
8. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
[TBL] [Abstract][Full Text] [Related]
9. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
[TBL] [Abstract][Full Text] [Related]
10. Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics.
Bertelmann T; Berndzen L; Raber T; Pfeiffer S; Leha A; Paul C; Feltgen N; Bemme S
Sci Rep; 2021 Dec; 11(1):24096. PubMed ID: 34916576
[TBL] [Abstract][Full Text] [Related]
11. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
[TBL] [Abstract][Full Text] [Related]
12. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
[TBL] [Abstract][Full Text] [Related]
13. Vitreomacular Changes after Intravitreal Gas Injection for Idiopathic Impending or Early Macular Hole: An Optical Coherence Tomography Study.
Tew TB; Chen TC; Yang CH; Yang CM
Ophthalmologica; 2018; 239(1):1-10. PubMed ID: 28954267
[TBL] [Abstract][Full Text] [Related]
14. Indications and outcomes for intravitreal injection of C
Guber J; Rusch C; Guber I; Scholl HPN; Valmaggia C
Sci Rep; 2021 Sep; 11(1):18089. PubMed ID: 34508148
[TBL] [Abstract][Full Text] [Related]
15. Treatment of primary full-thickness macular hole by intravitreal injection of expansile gas.
Han R; Zhang C; Zhao X; Chen Y
Eye (Lond); 2019 Jan; 33(1):136-143. PubMed ID: 30185833
[TBL] [Abstract][Full Text] [Related]
16. Pneumatic Vitreolysis for Management of Symptomatic Focal Vitreomacular Traction.
Chan CK; Mein CE; Crosson JN
J Ophthalmic Vis Res; 2017; 12(4):419-423. PubMed ID: 29090053
[TBL] [Abstract][Full Text] [Related]
17. BASELINE CHARACTERISTICS OF VITREOMACULAR TRACTION PROGRESSING TO FULL-THICKNESS MACULAR OR LAMELLAR HOLES IN THE PHASE III TRIALS OF ENZYMATIC VITREOLYSIS.
Schneider EW; Jaffe GJ
Retina; 2020 Aug; 40(8):1579-1584. PubMed ID: 31415451
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Vitreomacular Traction with Intravitreal Injection of Perfluoropropane.
Veith M; Penčák M; Ernest A; Straňák Z
Cesk Slov Oftalmol; 2019; 75(4):182-187. PubMed ID: 32397720
[TBL] [Abstract][Full Text] [Related]
19. Vitreomacular traction in diabetic retinopathy.
Hsieh YT; Yang CM
Jpn J Ophthalmol; 2024 Jan; 68(1):12-18. PubMed ID: 38001367
[TBL] [Abstract][Full Text] [Related]
20. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole.
Duker JS; Kaiser PK; Binder S; de Smet MD; Gaudric A; Reichel E; Sadda SR; Sebag J; Spaide RF; Stalmans P
Ophthalmology; 2013 Dec; 120(12):2611-2619. PubMed ID: 24053995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
